In 8 to 14% of patients with AML, TP53 mutations have been recognized.11, 12Mutations and/or deletions of TP53 have been intently linked with complex karyotype AML, resistance to chemotherapy, older age, and overall survival.2, 13. This evidence concerns the gene TP53 and acute myeloid leukemia.